Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Biopharma Holdings (XERS) has announced the granting of restricted stock units (RSUs) to 19 new employees as part of its Inducement Equity Plan. The Compensation Committee of Xeris' Board of Directors approved the grants on January 2, 2025, consisting of an aggregate of 181,500 shares of common stock.
The RSUs will vest over a three-year period in equal annual installments, contingent upon the employees' continued employment with Xeris or its subsidiaries. These equity awards were granted exclusively to new hires as an employment inducement under NASDAQ Listing Rule 5635(c)(4).
Xeris Biopharma Holdings (XERS) ha annunciato l'assegnazione di azioni vincolate (RSU) a 19 nuovi dipendenti nell'ambito del suo Piano di Equity di Induzione. Il Comitato per la Compensazione del Consiglio di Amministrazione di Xeris ha approvato le assegnazioni il 2 gennaio 2025, per un totale di 181.500 azioni di azioni ordinarie.
Le RSU matureranno in un periodo di tre anni in rate annuali uguali, a condizione che i dipendenti rimangano in servizio presso Xeris o le sue filiali. Questi premi azionari sono stati concessi esclusivamente a nuovi assunti come incentivo all'occupazione ai sensi della Regola di Quotazione NASDAQ 5635(c)(4).
Xeris Biopharma Holdings (XERS) ha anunciado la concesión de unidades de acciones restringidas (RSUs) a 19 nuevos empleados como parte de su Plan de Capital de Inducción. El Comité de Compensación de la Junta Directiva de Xeris aprobó las concesiones el 2 de enero de 2025, consistiendo en un total de 181,500 acciones de acciones ordinarias.
Las RSUs se consolidarán durante un período de tres años en cuotas anuales iguales, condicionadas a la continuación del empleo de los empleados en Xeris o sus subsidiarias. Estos premios de capital se otorgaron exclusivamente a nuevas contrataciones como inducimento a la empleabilidad según la Regla de Listado NASDAQ 5635(c)(4).
Xeris Biopharma Holdings (XERS)는 유도 자본 계획의 일환으로 19명의 신규 직원에게 제한된 주식 단위(RSU)를 부여한다고 발표했습니다. Xeris 이사회의 보상 위원회는 2025년 1월 2일에 총 181,500주의 보통주를 부여하는 것을 승인했습니다.
RSU는 3년 동안 매년 동일한 비율로 발효되며, 직원들이 Xeris 또는 그 자회의 고용을 지속하는 조건입니다. 이 자본 보상은 NASDAQ 상장 규칙 5635(c)(4)에 따라 새로운 채용자에게만 부여되었습니다.
Xeris Biopharma Holdings (XERS) a annoncé l'octroi d'unités d'actions restreintes (RSU) à 19 nouveaux employés dans le cadre de son Plan de Capital d'Induction. Le Comité de Rémunération du Conseil d'Administration de Xeris a approuvé les octrois le 2 janvier 2025, pour un total de 181 500 actions ordinaires.
Les RSU seront acquises sur une période de trois ans par tranches annuelles égales, sous réserve de la poursuite de l'emploi des employés au sein de Xeris ou de ses filiales. Ces récompenses en actions ont été accordées exclusivement aux nouvelles recrues en tant qu'incitation à l'emploi conformément à la Règle de Cotation NASDAQ 5635(c)(4).
Xeris Biopharma Holdings (XERS) hat die Vergabe von Restricted Stock Units (RSUs) an 19 neue Mitarbeiter im Rahmen seines Inducement Equity Plans bekannt gegeben. Der Vergütungsausschuss von Xeris' Vorstand genehmigte die Zuteilungen am 2. Januar 2025, die insgesamt 181.500 Aktien gewöhnlicher Aktien umfassen.
Die RSUs werden über einen Drei-Jahres-Zeitraum in gleichen jährlichen Raten fällig, abhängig von der fortgesetzten Beschäftigung der Mitarbeiter bei Xeris oder seinen Tochtergesellschaften. Diese Eigenkapitalauszeichnungen wurden ausschließlich neuen Mitarbeitern als Beschäftigungsanreiz gemäß der NASDAQ-Listing-Regel 5635(c)(4) gewährt.
- Successful attraction of new talent with 19 new employees
- Strategic use of equity-based compensation to align employee interests with company growth
- Potential dilution of existing shareholders through issuance of 181,500 new shares
Xeris’ Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Xeris or one of its subsidiaries as an inducement material to such individual's entering into employment with Xeris or one of its subsidiaries, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. The restricted stock units will vest over a period of three years in equal annual installments and are subject to the employees’ continued employment with Xeris or one of its subsidiaries. All equity awards are subject to the terms and conditions of Xeris’ Inducement Equity Plan and forms of award agreements covering the grants.
About Xeris
Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing’s syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection of levothyroxine for hypothyroidism as well as multiple early-stage programs leveraging Xeris’ technology platforms, XeriSol® and XeriJect®, for its partners.
Xeris Biopharma Holdings is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250106342979/en/
Allison Wey
Senior Vice President, Investor Relations and Corporate Communications
awey@xerispharma.com
Source: Xeris Biopharma Holdings, Inc.
FAQ
How many restricted stock units did Xeris (XERS) grant on January 2, 2025?
What is the vesting schedule for Xeris' (XERS) January 2025 RSU grants?
How many new employees received RSU grants from Xeris (XERS) in January 2025?
Under which NASDAQ rule did Xeris (XERS) grant these inducement awards?
